Zero Gravity Bioprinter is Ready for Delivery to the International Space Station

Share this Article

An amazing thing happened two years ago, when Techshot and nScrypt worked together to 3D print a human heart – in zero gravity. Not a working heart, yet, but the two companies were the first to 3D print cardiac and vascular structures in zero gravity using adult human stem cells. Why would they do such a thing, you might ask? The reasoning is much more than “because they can,” as 3D bioprinting in zero gravity is actually easier and more effective than it is on Earth.

Earth-based bioprinting requires thick, viscous bioinks that can contain chemicals or other materials necessary for providing structural support. The lack of gravity in space, however, means that thinner, purer bioinks can be used, as well as thinner print nozzles, allowing for more precision and control. When the first viable human organ is 3D printed, it may very well happen in space.

After nScrypt and Techshot pulled off their successful zero-G bioprinting feat, they began work on the 3D BioFabrication Facility, or BFF, a 3D bioprinting system for the International Space Station. The BFF can 3D print thick tissue and organs using adult stem cells. The printing will happen on an nScrypt 3D Bio Assembly Tool, or BAT; the bioink will be printed into a specialized cell culturing bioreactor cassette designed by TechShot and conditioned in the TechShot ADvanced Space Experiment Processor (ADSEP). The BFF and ADSEP are scheduled to launch on their way to the ISS in February 2019.

The nScrypt BAT 3D printer features high-precision motion and extreme dispensing control, and will use nScrypt’s patented SmartPump, which has 100 picoliter volumetric control and uses super-fine nozzles, down to 10 microns, to dispense biomaterials. This enables the highly controlled and repeatable placement of bioink, which is necessary for printing the fine details of tissues and organs.

“Especially when dealing with something as important as tissue, it is vital to place the correct amount of material in the correct position every time,” said nScrypt CEO Ken Church. “This is what our machines offer and what has contributed to our success in bioprinting as well as other applications. This is an exciting time for discovery and more importantly a time of impact for those that are seriously seeking solutions to grow thick vascularized tissue, which is the basis for a fully printed organ.”

The first complete print, after the initial test prints, will be a cardiac patch for damaged hearts. Cells will be printed into the bioreactor cassette, and the bioreactor will then provide media perfusion to deliver nutrients and remove toxins from the tissue, keeping it alive while providing electrical and mechanical stimulus to encourage the cells to become beating heart tissue.

Rendering of the BFF in an EXPRESS rack [Image: nScrypt]

The BFF may truly be an astronaut’s BFF; in addition to 3D printing tissue for people on Earth, it can print pharmaceuticals and even food on demand for people on the International Space Station.

“We are very excited to see this project, and all that it can provide, come to life,” said Techshot President and CEO John C. Vellinger. “With the goal of producing everything from organs, to pharmaceuticals, to perhaps even food, the BFF has the ability to improve the lives of people on earth and help enable deep space exploration.”

Discuss this and other 3D printing topics at 3DPrintBoard.com or share your thoughts below. 

 

Share this Article


Recent News

3D Printing Webinar and Event Roundup: October 6, 2024

3D Printing News Briefs, October 5, 2024: JIMTOF, Sensors, Façades, & More



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

3D Printing Market Reaches $3.45B in Q2 2024, Marking 8.4% Year-Over-Year Growth

The global 3D printing market continued its upward trajectory in the second quarter of 2024, totaling $3.45 billion—a year-over-year increase of 8.4%. Despite a slight sequential decline from $3.47 billion...

Unlocking the Future of Investment Casting: 3D Systems’ Patrick Dunne on QuickCast Air

On the floor of this year’s International Manufacturing Technology Show (IMTS), the theme for original equipment manufacturers (OEMs) in additive manufacturing (AM) seemed to be indirect production. What if, by...

3D Printing Unpeeled: Screen Printing Drugs, Repair Process for Marines & PCL Drug Release

Contract development and manufacturing organization (CDMO) Adare Pharma Solutions, is partnering with Laxxon Medical. The CDMO will use Screen-Printed Innovative Drug (SPID) to make oral dosage forms where they hope...

Featured

FDA Clears 3D Systems’ New Multi-Material Solution for 3D Printed Dentures

3D Systems (NYSE: DDD), the additive manufacturing (AM) industry pioneer based in South Carolina, has achieved Food and Drug Administration (FDA) clearance for its one-piece, multi-material denture printing solution. 3D...